HYFT

NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - Artificial intelligence has become the most talked-about tool in drug discovery, promising to compress the years and billions of dollars it takes to turn a biological insight into a medicine. But most of the AI now aimed at biology shares a hidden limitation: it reasons primarily from sequence, the raw genetic letters of DNA, RNA, and proteins. Two molecules whose sequences look alike are treated as related; two that look different are treated as unrelated. That assumption is convenient, and it is often wrong, because biology repeatedly reaches the same function through completely different-looking structures. A c

AUSTIN, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and two that do not are treated as unrelated. That assumption is convenient and it is frequently wrong, because biology routinely arrives at the same functional outcome through structures that share no obvious sequence similarity. MindWalk Holdings Corp. (NASDAQ:HYFT) has built its entire technology stack around that gap, and in late July it put the result on a stage in front of the AI infrastructure industry. Three Layers, One Idea MindWalk describes itself as a Bio-Native AI c

EFFECT - MindWalk Holdings Corp. (0001715925) (Filer)

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

Issued on behalf of MindWalk Holdings Corp. (NASDAQ:HYFT)USA News Group News CommentaryNEW YORK, July 23, 2026 /CNW/ -- For years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of companies can talk about accelerating the search for new medicines; far fewer can point to real revenue, real clients, and a business model that compounds. One small-cap AI biotech just put a set of numbers behind its version of that story, and they show a company whose pivot is starting to appear in its financials rather than only in its slide decks. The company reported full-year resu

20-F - MindWalk Holdings Corp. (0001715925) (Filer)

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

Full-year revenue rose 46% to $15.6 million with gross margin expanding to 59%; net loss narrowed by more than half as MindWalk sharpened its focus on the BioIntelligence infrastructure powering AI drug discovery. MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a Bio-Native AI company, today reported financial results for the fiscal year ended April 30, 2026. All figures are in Canadian dollars unless otherwise noted. Fiscal 2026 was the year MindWalk completed its transition from building its technology to deploying it. Revenue grew 46% year over year, gross margin expanded, the net loss narrowed by more than half, and the Company divested a non-core business to concentrate on the

Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H

F-3 - MindWalk Holdings Corp. (0001715925) (Filer)

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

MindWalk to host an earnings conference call and webcast MindWalk Holdings Corp. ("MindWalk" or the "Company") (NASDAQ:HYFT), a Bio-Native AI company, today announced that it will report financial results for the fourth quarter and full fiscal year 2026 and host a conference call on Wednesday, July 22, 2026, at 5:00 p.m. Eastern Time. Financial results will be issued in a press release prior to the call, which will include a management presentation followed by a question-and-answer session. Conference Call and Webcast Details Event Date and Time: Wednesday, July 22, 2026, at 5:00 p.m. Eastern Time The conference call will be webcast live and available for replay via a link provided

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

Inclusion in FTSE Russell's June 2026 semi-annual  reconstitution expands visibility among institutional investors and broadens eligibility for  index-tracking funds managing more than $12 trillion in benchmarked assets MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a Bio-Native AI company, today announced that it has been added to the Russell 3000E Index, effective after the U.S. market close on June 26, 2026, as part of the FTSE Russell June 2026 semi-annual Russell US Indexes Reconstitution. Membership was reconfirmed in index data published June 29, 2026. The Russell 3000E Index is FTSE Russell's broadest measure of the U.S. equity market, covering up to the 4,000 of the larges

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ:ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, "Partnering to Power the New Era of Drug Discovery," will be held on Monday, June 15, 2026, at 12:00 p.m. ET. Moderated by Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail, the panel will explore how the convergence of high-performance compute, native biological knowledge representations, and generative AI can dismantle longstanding barriers in drug discover

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

ReefIQ turns fragmented biological data into governed, queryable context for AI-enabled drug discovery and biologics development. MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a bio-native AI company, today launched ReefIQ™, a HYFT-powered biological context layer for AI drug discovery and biologics development, that sits between client discovery data and AI reasoning workflows. Biology is connected, but drug-discovery data is often fragmented across files, formats, systems, teams, and workflows. ReefIQ reconnects those representations before AI workflows act on them, linking fragmented data into MindWalk's biological representation foundation. Sequences, structures, assay outputs

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

HYFT® technology computationally identified and prioritized a pan-serotype dengue target before immunization. Preclinical data support the prediction at the binding level: immunization with immunogens designed on the predicted target elicited antibodies that cross-react with antigens of all four dengue serotypes, and scrambled-sequence controls support that the response is specific to the designed immunogen rather than background reactivity. MindWalk Holdings Corp. (NASDAQ:HYFT) today reported preclinical dengue data that support a computational prediction its HYFT® platform generated before any animal was immunized. HYFT® computationally identified a candidate pan-serotype structural tar

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

MindWalk Holdings Corp. (NASDAQ:HYFT), a bio-native AI therapeutic research and technology company, today announced the launch of its Pandemic Response Platform, a deployment configuration of the Company's proprietary HYFT® biological pattern system and LensAI™ platform purpose-built for outbreak preparedness, rapid countermeasure design, and pan-strain antigen and antibody generation against RNA viruses. The Platform draws on the same biological intelligence infrastructure that has supported more than 20 molecules advanced to the clinic across the Company's programs, and is currently deployed on its wholly owned pan-serotype Dengue and universal Influenza programs, both at in vivo proof-of

6-K - MindWalk Holdings Corp. (0001715925) (Filer)